1 / 42

LDN Rx at SIG: 2005-2016, N>1400

LDN for Autoimmune and Inflammatory Diseases Leonard Weinstock, MD Associate Professor of Clinical Medicine Washington University School of Medicine President, Specialists in Gastroenterology. LDN Rx at SIG: 2005-2016, N>1400. Alopecia areata Chronic fatigue synd. Chronic pelvic pain

pinedam
Download Presentation

LDN Rx at SIG: 2005-2016, N>1400

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. LDN for Autoimmune and Inflammatory DiseasesLeonard Weinstock, MDAssociate Professor of Clinical MedicineWashington University School of MedicinePresident, Specialists in Gastroenterology

  2. LDN Rx at SIG: 2005-2016, N>1400 • Alopecia areata • Chronic fatigue synd. • Chronic pelvic pain • Complex regional pain ^ • Constipation * • Dercum’s disease • Eczema • Fibromyalgia * • Ganglionopathy ^ • HIV * • Inflammatory bowel dis. *^ • Irritable bowel syndrome * • Multiple sclerosis *^ • Restless legs syndrome * • Rheumatoid arthritis • Sarcoidosis ^ • SIBO * * Published; ^ To be discussed

  3. Outline • History of LDN • Mechanisms of action of LDN • Autoimmune and inflammatory diseases • Crohn’s disease • Ulcerative colitis • Sarcoidosis • Autonomic ganglionopathy • Complex regional pain syndrome • Multiple sclerosis

  4. LDN Hx: Modulator of Opioid & Receptor Activity (MORA) • Zagon et al. Science 1983;221:671-3. 1979-81: MOA studied (Zagon – Penn State) 1985: Rx for AIDS (Bihari) Mid 90’s: Rx for MS (Bihari) LDN = low dose naltrexone (1.0- 4.5 mg/d) vs. 50mg–100mg daily for opiate and alcohol dependence (FDA IND 1985) vs. ultra low dose 0.001 mg in Oxytrex

  5. Endogenous opioids& receptors • Peptides: B-endorphin, enkephalins, endomorphin, dynorphin • Receptors • CNS and PNS • GI tract • Myenteric plexus • Mucosal plexus • Endocrine cells of intestinal mucosa • Lymphocytes

  6. Endorphins • Endorphins produced in most cells • Regulate cell growth including immune cells • Disorders of the immune system can occur with unusually low levels of these endorphins • Met-Enkephalin is the most influential endorphin

  7. Opioid Growth Factor (OGF) Met-Enkephalin = Opioid Growth Factor OGF binds to the Opioid Growth Factor Receptor (OGFr) Two elements are required for health: opioid production and cell interaction

  8. Methionine enkephalin: role in immunoregulation MENK binds to opioid receptors on immune and cancer cells. Binding site: CD4+Foxp3+ regulatory T cells (Tregs) which suppressing immune system to keep balanced immunity Tregs reveal a relationship between the endocrine and immune systems Zhao. IntImmunopharmacol 2016;37:59-64. Li. Cancer BiolTher2015;16:450-9.

  9. MENK & immunology & cancer MENK delayed development of tumor in S180 tumor bearing mice and down-regulated level of Tregs Cancer study – 50 pts – isolated lymphocyte subpopulation evaluations in peripheral blood before and after culture with MENK MENK inhibited CD4+T cells, CD8+T cells, CD4+CD25+ Tregs and natural killer cells Wang. Hum VaccinImmunother2014;10:1836-40.

  10. LDN MOA LDN blocks the OGF receptors only for a few hours – leads to a rebound effect; in which both the production and utilization of OGF is greatly increased. Endorphins now interact with the more-sensitive and more-plentiful receptors and assist in regulating cell growth and immunity

  11. LDN MOA Reduces/regulated T-cells, Natural Killer cells, IL-2 and TH-1 improve native immune system Shift from TH1 to TH2 decreases general inflammation

  12. Additional MOA – Toll receptors Li. Med Hypotheses 2012;79:754-6. Hutchinson et al. Brain Behav Immun 2010;24:83-95. • Endothelial receptors – possible MOA for IBD • GI receptor allows for increase in bacterial translocation – exacerbated by exogenous opioids • LDN may stabilize receptor and decrease bacterial translocation • Glial receptor • Activated microglia cause neuroexitability and enhanced pain via toll-like receptor 4 pathway • LDN antagonizes pathway

  13. LDN & inflammatory bowel diseases First reported in Crohn’s disease Subsequently reported in ulcerative colitis Both related to autoimmune, inflammatory, and microbiome disturbances with active cytokines

  14. Case 1 • 40 y.o. WF with Crohn’s disease – s/p total colectomy, recurrence in ileum 4 yrs later • Failing infliximab: diarrhea and fatigue

  15. Case 1 • Addition of LDN 4.5 mg • Endoscopic and sx’ic remission within 2 mo

  16. Crohn’s disease – 3 open label studies • Smith. LDN therapy improves active Crohn's disease. Am J Gastroenterol 2007;102:820-828. • Shannon. LDN for treatment of duodenal Crohn’s disease in a pediatric patient. Inflamm Bowel Dis 2010;16:1457.

  17. Crohn’s disease - LW • Open label study: 4.5 mg LDN in moderate • to severe CD (N=33 adults) • Failing 5-ASA followed by 6-MP and/or IFX • LDN Rx: 40 ±43 wks (max 200 wks) • 5 withdrew - AE (mild-mod) • Positive clinical response in 15/33 pts • 11 of 15 responders: C-scope before and after Rx: 8 complete healing, 1 partial healing and 2 unchanged • Weinstock. J Clin Gastro 2014

  18. Crohn’s disease – RCT #1 • LDN as adjunctive therapy in adults • Biologic therapy was an exclusion • 88% of LDN (N=18) had 70-point decrease in CDAI scores vs. 40% of control (N=16) • After 12 wks, 78% of LDN had response in CD endoscopy index severity score vs. 28% controls • 33% of LDN had endoscopic remission vs. 8% controls Smith et al. Dig Dis Sci 2011;56:2088-97.

  19. Crohn’s disease – RCT #2 • LDN as sole therapy in 14 children • LDN (0.1 mg/kg) vs. placebo for 8 wks • CDAI: 34±3 decreased to 22±4 (P=0.005) • 25% went into remission • No serious AE Smith et al. J ClinGastroenterol 2013;47:339-345.

  20. Fibromyalgia: RTC study • LDN 4.5 mg/day vs. placebo • N=31 women • Randomized, double-blind, placebo-controlled, counterbalanced, x-over study. • Questionnaires to measure daily levels of pain. Secondary outcomes included general satisfaction with life, positive mood, sleep quality and fatigue Younger et al. Arthritis Rheum 2013 Feb;65:529-38.

  21. Fibromyalgia: RTC study • LDN 4.5 mg/day vs. placebo • N=31 women • Randomized, double-blind, placebo-controlled, counterbalanced, x-over study. • Questionnaires to measure daily levels of pain. Secondary outcomes included general satisfaction with life, positive mood, sleep quality and fatigue Younger et al. Arthritis Rheum 2013 Feb;65:529-38.

  22. Fibromyalgia: RTC study (cont.) • 28.8% pain reduction with LDN vs. 18.0% reduction with placebo (P = 0.016) • LDN improved general satisfaction with life (P = 0.045) and improved mood (P = 0.039) • 32% had a significant reduction in pain plus a significant reduction in either fatigue or sleep problems vs. 11% response rate with placebo (P = 0.05) • LDN equally tolerable as placebo. No serious side effects were reported Younger et al. Arthritis Rheum 2013 Feb;65:529-38.

  23. Sarcoidosis • Granulomatous disorder with T-cells • & macrophages in multiple organs • CD3+ cells, CD4+ cells w/ HLA-DR antigen, & high CD4/CD8 ratio in bronchus • CD4+ CD29+ memory T-cells increased Iida K et al. Thorax 1997;52:431-7.

  24. Sarcoidosis • Special T-cell interactions in pulmonary and liver sarcoidosis • Activated memory T-cells with CD11a Iida K et al. Thorax 1997;52:431-7.

  25. Sarcoidosis: Pathogenesis • Genetic susceptibility with functional polymorphisms • Exposure to antigens leading to activation of macrophages • Attainment of T-cell immunity against antigens mediated by antigen processing and presentation by macrophage Zissel

  26. Sarcoidosis vs. Crohn’s disease • Similar pathology • Unregulated T-cell activity • Non-caseating granulomas

  27. Sarcoidosis Rx: Role for LDN • Regulate T-cell growth – (Treg) • Regulate B-cell growth • Decrease inflammation • Decrease permeability • Stabilize Toll-like receptors • Decrease microglia activation • Decrease cytokine release • Shift from TH2 to TH1 • Improve GI motility

  28. Sarcoid Case 1 Rash Fatigue Adenopathy Liver/Spleen

  29. Case 1 • AH 73 y.o. AAF – supraglotic resection in 2001 d/t sarcoidosis. Sx weak voice, painful rash, fatigue, and parotitis • Rash prevention • by minocycline • Hx MTX neuropathy • Referred abnl CT • LDN – prescribed

  30. Progress 2015 February - LDN 1 mg/day March - less dyspnea, fatigue, able to stop minocycline w/o rash March – LDN increased 12 days to 4.5 mg May – Dec - less DOE, more energy July & Dec – CT’s showed reduction in the size of the splenic lesions and liver lesions

  31. 12/2014 11/2011 Before LDN

  32. 12/12 - 10 mo LDN 7/15 - 5 mo LDN

  33. 12/15 – 10 mo LDN 12/14

  34. Sarcoid Case 2 Pulmonary Fatigue

  35. Case 2: PFB 64 y.o. AAF • 26 yr pulmonary sarcoidosis • 2 yr home O2 (24 hr/d; 2 L) • Dyspnea (rest/activity) and dry cough • 7/15 - Prednisone 20 mg • Last used 16 yr ago • 8/15 - LDN

  36. Case 2: PFB 64 y.o. AAF • 9/15 – 1 mo LDN • No change • 10/15 - 2 mo LDN • Less fatigue • Less dyspnea • O2prn for vigorous activity • Prednisone taper started

  37. Sarcoid Case 3 Pulmonary

  38. Case 3: PLB 63 y.o. WM • Abnl CXR 17 yr ago – Bx: granulomas • Hx osteopenia • 2 yrs dyspnea with activity • 8/20/15 - LDN • 4.5 mg (titrated up from 1.5 over 2 wks)

  39. Case 3: PLB 63 y.o. WM • 1 mo after LDN – unchanged • 2 mo after LDN – less short of breath • 3 mo after LDN – asthma from allergens

  40. Sarcoidosis Rx: Role for LDN Experience needed – enroll AA pts • Pulmonary response w treadmill testing • Anti-inflammatory markers

  41. LDN side effects: neurologic Ploesser J, Weinstock LB, Thomas E. Internat J Pharm Compound 2010:171-173. • Anxiety 15.7% • Drowsiness 11.6% • Headache 11.6% • Insomnia 8.3% • Muscle pain 8.3% • Vivid dreams 5.0% • Mood change 3.3% • Trouble concentration 1.7%

  42. LDN: additional side effects Ploesser J, Weinstock LB, Thomas E. Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders. Internat J Pharm Compound 2010:171-173. • Nausea 12.4% • Abd. pain 11.6% • Diarrhea 8.3% • Anorexia 8.3% • Rash, hot flashes, weight gain 0.1% each

More Related